GH Research PLC (NASDAQ:GHRS – Free Report) – Research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for GH Research in a research report issued on Tuesday, May 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.29) per share for the quarter, down from their previous forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for GH Research’s Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.21) EPS, Q1 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.47) EPS and FY2027 earnings at ($1.64) EPS.
Several other equities research analysts have also recently weighed in on the company. Citigroup reiterated an “outperform” rating on shares of GH Research in a research report on Friday, May 15th. Royal Bank Of Canada boosted their price objective on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a report on Tuesday, April 21st. Cantor Fitzgerald boosted their price objective on GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, Guggenheim set a $34.00 price objective on GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.38.
GH Research Stock Up 2.7%
Shares of GHRS opened at $22.54 on Thursday. The business’s 50-day moving average price is $17.52 and its 200-day moving average price is $15.72. GH Research has a twelve month low of $10.66 and a twelve month high of $24.66. The stock has a market cap of $1.55 billion, a PE ratio of -24.50 and a beta of 1.27.
GH Research (NASDAQ:GHRS – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04).
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of GHRS. JPMorgan Chase & Co. purchased a new position in shares of GH Research during the second quarter worth about $79,000. BNP Paribas Financial Markets grew its holdings in shares of GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after purchasing an additional 10,600 shares in the last quarter. Osaic Holdings Inc. boosted its stake in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares in the last quarter. AdvisorShares Investments LLC boosted its stake in GH Research by 41.1% in the third quarter. AdvisorShares Investments LLC now owns 53,991 shares of the company’s stock worth $772,000 after buying an additional 15,735 shares in the last quarter. Finally, CenterBook Partners LP purchased a new stake in GH Research in the third quarter worth approximately $2,376,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.
GH Research Company Profile
GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.
The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.
Further Reading
- Five stocks we like better than GH Research
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
